Mylan win in US court may hit Ranbaxy Ranbaxy might lose the 180-day opportunity to exclusively sell its generic version of Novartis’ blockbuster hypertension drug Diovan if the US district court rules in favour of Mylan Inc, which has sued the US Food and Drug Administration (USFDA) for refusing it an approval for the generic drug. [News Source]